索拉非尼联合表阿霉素对乳腺癌MCF-7细胞增殖作用的影响及机制  

Effects of sorafenib and epirubicin on the proliferation of breast carcer MCF-7 cell in vitro and its mechanism

作　　者：胡燕[1] 黄宇贤[1] 陈晓华[1] 罗荣城[1] 

机构地区：[1]南方医科大学南方医院,广州510515

出　　处：《山东医药》2010年第11期37-39,共3页Shandong Medical Journal

摘　　要：目的探讨索拉非尼联合表阿霉素对乳腺癌MCF-7细胞增殖作用的影响及可能机制。方法MTT法测MCF-7细胞培养1—14d的吸光度，绘制生长曲线并在第14天检测其体外克隆形成率。于24、48、72h分别测索拉非尼及表阿霉素半数抑制浓度（IC50）值。实验分为空白对照组、索拉非尼单药组、表阿霉素单药组、联合组。根据索拉非尼及表阿霉素的IC50值设定联合给药浓度及时间，用MTT法测定72h时索拉非尼及表阿霉素单用组与联合组MCF-7细胞的增殖抑制率。结果生长曲线示MCF-7细胞在1—4d生长速度较快，之后减慢，10d后生长趋于停滞。MCF-7细胞在14d的克隆形成率为37．2％。索拉非尼24、48、72h的Ic50值分别为（7．85＋0．86）、（3．45＋0．16）、（2．10＋0．64）μmol／L，表阿霉素24、48、72h的IC50值分别为（6．52＋0．62）、（1．61＋0．82）、（1．13＋0．51）μmol／L。72h时索拉非尼组MCF-7抑制率明显低于表阿霉素组，MCF-7抑制率高于其他两组（P〈0．05），细胞抑制率随药物浓度增加而增加（P〈0．05）。结论索拉非尼联合表阿霉素对乳腺癌细胞MCF-7细胞增殖有抑制作用；其机制可能是两药联用抑制或阻断了细胞增殖和生存相关因素的作用。Objective To investigate the effect of sorafenib and epirubicin （EPI） on the proliferation of breast career MCF-7 cells and its probable mechanism. Methods MTT assay was utilized to detect the light absorbance（A） from day 1 to 14 to determine growth kinetics. Giemsa was utilized to detect the cloning efficiency of MCF-7 cells. The IC50 of sorafenib and EPI was assessed after the MCF-7 cells incubated for 24,48,72 h. The best concentration and time of coadministration was decided acorrding to the IC50 results. Four different groups were set up, they were control group, sorafenib group, EPI group, sorafenib ＋ EPI group. The inhibitory effects of sorafenib, EPI and sorafenib ＋ EPI treatment on MCF-7 proliferation in vitro were assessed by MTr assay after incubated for 72 h. Results The growth curve showed that the growth velocity of MCF-7 cells was fast at the first 4 days, but slowed down 5 days after, and stayed at a standstill in last stage. The cloning efficiency of MCF-7 cells was 37.2%.The IC50 of Sorafenib at 24,48,72 h are （7.85 ±0.86） ,（3.45 ±0.16） ,（2.10 ± 0.64 ）μ mol/L, the IC50 of EPI at 24,48,72 h were （ 6.52±0.62 ）, （ 1. 61± 0.82 ）, （ 1.13± 0.51 ） μmol/L. Sorafenib and EPI both significantly inhibited the proliferation of MCF-7 cells at 72 h, showiong a synergistic effect of their actions in combined use（P 〈 0.05 ）. In the combination group ,the inhibition rate increased as the concentration of administration increased （ P 〈 0.05 ）. Conclusion Sorafenib and EPI have synergistic effects in inhibiting the proliferation of MCF-7 cells.

关 键 词：乳腺肿瘤 乳腺癌 索拉非尼 表阿霉素 药物疗法 

分 类 号：R979.1[医药卫生—药品] R737.9[医药卫生—药学]